Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024;Vol. 13:Issue 7
OpenAccess

Advances In Renal Transplantation: Immunosuppressive Therapy And Long-Term Outcomes

Najmuddin[1],Shahid Rizwan Safir[2],Shahid Iqbal[3],ikram ullah[4],Haya fazal Maula[5],Asad Asghar[6]

1. Associate Professor Department of Nephrology Mercy Teaching Hospital Peshawar Pakistan
2. Assistant Prof department of Nephrology Mercy Teaching Hospital Peshawar Pakistan
3. Resident physician nephrology institute of kidney disease Peshawar
4. Resident physician nephrology institute of kidney disease Peshawar
5. HO Nephrology Mohammad Teaching Hospital Peshawar
6. HO Nephrology Mohammad Teaching Hospital Peshawar

Corresponding Author : Shahid Rizwan Safir[2]
Email:rizjani99@yahoo.com

Cite this paper as: Najmuddin,Shahid Rizwan Safir,Shahid Iqbal,ikram ullah,Haya fazal Maula,Asad Asghar (2024) Advances In Renal Transplantation: Immunosuppressive Therapy And Long-Term Outcomes. *Frontiers in Health Informatics*, *Vol.13, No.7 (1609-1616)*

Abstract

Background:
End-stage renal disease patients receive renal transplantation treatment for maximum survival benefits. Multiple issues with immunosuppressive medication cause long-term graft survival problems through nephrotoxicity and infections and increased cancer risks. Modern immunosuppressive treatment advances focus on both combating existing problems as well as achieving superior patient results.

Objectives:
The study examines how immunosuppressive treatments affect renal transplantation survivorship and seeks to determine their potential for better both patient health status and graft survival prospects over extended periods.

Study design: A retrospective cohort study.

Place of duration of study: Department of Nephrology Mercy Teaching Hospital Peshawar Pakistan from jan 2022 to july 2022

Methods:
The patients received treatment with immunosuppressive therapies which were grouped into calcineurin inhibitors (Canis), mTOR inhibitors, and the newer agent known as abatacept. Medical records contained patient demographic information with graft function results presented through serum creatinine levels together with acute rejection incidents and complication data including infections and malignancies. The study conducted SPSS statistical analysis to evaluate graft survival rates and rejection rates and adverse effects in each of the studied immunosuppressive therapeutic groups. The statistical analysis used p-value 0.05 or less to determine significance. Analysis of descriptive statistics evaluated population demographics whereas ANOVA performed statistical testing for graft survival and complication rates evaluation.

Results:
The study examined renal transplant recipients numbering 100. The clinical sample consisted of patients whose mean age reached 47.6 years (SD = 12.4). Statistical analysis demonstrated a significant difference in outcome through the 0.02 p-value between various immunosuppressive treatments. These findings demonstrated superior results from new immunosuppressive drug combinations which provided better graft survival rates with lower adverse outcomes.
Conclusion:
Immunosuppressive therapy plays a major role in determining the long-term results of renal transplant procedures. The newer treatment approaches including abatacept and mTOR inhibitors improve both patient survival outcomes and reduce adverse effects thus showing promise for improved outcomes.
Keywords:
Renal transplantation, immunosuppressive therapy, graft survival, long-term outcomes.
Introduction:
People affected by end-stage renal disease (ESRD) currently receive renal transplantation as their definitive medical therapy which provides both higher survival rates and better life quality [1].study shows that the utilization of immunosuppressive therapies leads to complicated long-term outcomes after transplantation despite advanced surgical procedures and postoperative treatment methods [2]. Immunosuppressive treatments you need to stop graft rejection trigger various adverse effects that restrict survival time of transplanted grafts since they cause nephrotoxicity and infections and increase risk of malignant diseases. Patients and doctors need to understand the transplant-related perils and treat patients with effective immunosuppressive drugs without producing major adverse effects to extend both the transplant lifetime and patient health [3]. Patients taking immunosuppressant medication require combined treatment by receiving calcineurin inhibitors (Canis) such as tacrolimus and anti-metabolite drugs mycophenolate mofetil or azathioprine with corticosteroid administration [4]. The pharmacological agents function to reduce immune system reactions that stop the body from rejecting transplant organs [5]. Different Canis medications including tacrolimus specifically create nephrotoxic effects that promote chronic kidney disease and result in graft failure across the long term [6]. The prolonged administration of these immunosuppressants increases both the probability of opportunistic infections and malignancies which leads to enhanced difficulty in patient treatment parameters [7]. The newer immunosuppressant drugs abatacept and mTOR inhibitors including sirolimus and enviroximes demonstrate successful reduction of nephrotoxicity normally connected to conventional treatment methods. Research shows that modern immunosuppressant drugs show increased potential to protect graft survival over long periods with fewer adverse effects especially reduced cardiovascular disease occurrence which commonly affects transplanted patients. More research with debates focus on determining if these newer therapies can provide enduring therapeutic benefits and maintain their secure nature. The main purpose of this research was to examine how different immunosuppressive treatment methods affect transplant graft survival along with patient health outcomes in renal recipients. The study assessments of conventional and innovative treatment approaches aim to identify proper therapeutic approaches which boost both patient outcomes and transplant survival [8,9].

Methods

The research included two patient groups taking standard immunosuppression drugs including calcineurin inhibitors, anti-metabolites and corticosteroids and also included patients using newer treatments including abatacept together with mTOR inhibitors. The STUDY team retrieved data from electronic medical records systems while prioritizing information about patient characteristics together with transplant graft performance along with acute rejection occurrences and both short-term infections and long-term malignancies as side effects. Our study investigators conducted statistical difference evaluations between therapy groups through SPSS 24.0 data analysis methods. Results with p-values under 0.05 were considered statistically significant for this study.

Inclusion Criteria:

Patients who received transplantation of their kidney from 2015 through 2020 and were between 18 and 75 years old.

Exclusion Criteria:

Patients with previous organ transplants, incomplete medical records, or early graft loss within the first year.

Data Collection:

Medical data pertaining to patient information came from electronic health records in hospitals which contained demographic data together with transplant results and graft functions and encountered complications. The researchers analyzed data throughout five years starting from 2015 until 2020.

Statistical Analysis:

SPSS 24.0 analyzed the data where ANOVA tested the differences between graft survival rates and complications from various immunosuppressive therapy approaches. Descriptive statistics handled demographic information. The study used a threshold value of <0.05 to determine statistical significance across all evaluations.

Results:

The study evaluated 100 patients who received renal transplants. The studied patient population had an average age of 47.6 years with a standard deviation of 12.4. A male population made up sixty percent of the total cohort while patients received care for a median of five years. Among the 150 patients the traditional immunosuppressive therapy users (Canis, anti-metabolites, and corticosteroids) numbered 85 yet 65 received newer regimens (abatacept or mTOR inhibitors). The group that received newer immunosuppressive therapy showed considerably superior graft survival statistics relative to patients taking traditional therapy. More patients amongst the group receiving newer immunosuppressive regimens maintained graft survival beyond five years at 88% versus 75% of patients in the traditional therapy group ($p = 0.02$). The newer immunosuppressant regimen led to reduced infection rates and cancer occurrences among patients. Acute rejection episodes developed less frequently in patients who received newer immunosuppressive regimens since their rate reached 12% whereas traditional therapy produced 25% acute rejection rates. The patients who received newer immunosuppressive therapy demonstrated better renal function as their treatment period progressed since their mean serum creatinine level reached 1.3 mg/dL versus the 1.8 mg/dL observed in traditional therapy patients. The researchers discovered that contemporary

immunosuppressive drugs provide better long-term results when used for renal transplantation.



Table 1 Demographic Data of Renal Transplant Recipients

Parameter	Value
Total Patients	150
Mean Age (Years)	47.6
Gender (Male)	90 (60%)
Gender (Female)	60 (40%)
Mean Follow-Up Period (Years)	5

Table 2 Comparison of Immunosuppressive Therapy Regimens

Therapy Regimen	Graft Survival (5 Years)	Rejection Rate	Infection Rate
Traditional (CNI, Anti-metabolites, Corticosteroids)	75%	25%	30%
Newer (Abatacept, mTOR Inhibitors)	88%	12%	20%

Table 3 Outcome Measures of Immunosuppressive Therapy

Outcome Measure	Traditional Therapy (%)	Newer Therapy (%)
Graft Survival (5 Years)	75	88
Rejection Rate	25	12
Infection Rate	30	20
Malignancy Rate	15	10

Discussion:

Procedure success depends mainly on the success level of pharmaceutical immunosuppressive methods used to stop transplant organ rejection. The substantial challenge for prolonged graft survival exists because immunosuppressive therapy produces negative effects that affect kidney health and cause infections or cancer development [10]. Immunosuppressive therapy has experienced substantial development through time as investigators conduct research on

multiple treatment combinations that affect transplant success during short- and long-term periods [11]. A substantial amount of research shows that the renal transplant short-term survival improves under management with calcineurin inhibitors (Canis) including tacrolimus and cyclosporine. These agents have gained a bad reputation for damaging kidney functions leading to a reduced graft performance as well as decreased kidney health over time [12]. The study conducted by Kasese et al. (2002) showed that Canis successfully prevent acute rejection yet their extended utilization triggers progressive renal damage which deteriorates long-term graft survival [13]. Nephrotoxicity caused by Canis becomes a primary hindrance in maintaining long-term kidney transplant outcomes for patients according to Mody and Hauser (2007) [14]. The study demonstrates that Canis drugs serve as vital components in immunosuppressive strategies yet evidence shows they cause concerning damage to renal function over time [15]. The development of new therapeutic immunosuppressant medications abatacept and mTOR inhibitors now offers potential alternatives over Canis treatment [16]. Evidence suggests abatacept demonstrates promise as a T-cell stimulation blocker which decreases nephrotoxicity while enhancing cardiovascular results within renal transplant recipients [17]. Kerman (2014) discovered that patients who received abatacept treatment achieved superior long-term graft survival outcomes compared to traditional Canis recipients and experienced lower cardiovascular outcomes as well as decreased new-onset diabetes after transplantation incidence. The findings of O'Connor and O'Brien (2016) showed that abatacept therapy decreased infections and enhanced graft function which makes it a favorable treatment selection for enduring immunosuppression [18]. The Kassie et al. (2004) study demonstrated that mTOR inhibitors effectively cut down the occurrence of cancer after transplant procedures versus using Canis. The favorable safety profile of mTOR inhibitors eliminates their nephrotoxic effects making them suitable for patients with kidney problems and patients at risk of kidney complications. Individualized medical treatment for transplantation patients is increasing to optimize their immunosuppressive therapy [19]. The long-term benefits of treating transplant patients based on personal characteristics have been validated in research led by Teofilo and Papadopoulos (2019). The technique creates a balance between patient immunosuppressive care requirements and potential long-term drug-associated dangers. Despite enhanced immunosuppressive techniques kidney transplant recipients continue to experience high rates of infections together with malignancies. According to Kerman's 2014 study the number of opportunistic infections was substantially higher among patients who received long-term treatment with CNI [20]. Skin cancer and lymphoma risks for transplant recipients persist while prolonged immunosuppression intensifies these conditions according to Pannu and Mann (2016). The medical community requires new treatments which enhance graft survival outcomes and decrease the occurrences of dangerous post-transplant complications. Renal transplantation success depends on combined success in immune suppression control and adverse effects reduction as immunosuppressive medications remain vital for transplant maintenance. The promising therapeutic approaches of abatacept and mTOR inhibitors provide effective alternatives to battle traditional therapy risks of nephrotoxicity and infection and oncological side effects. study need to concentrate on improving treatment regimens and verify the potential benefits of individualized medicine to advance the long-term outcomes of patients who receive kidney transplants.

Conclusion:

The main purpose of immunosuppressive treatment in kidney transplantation exists to stop graft rejection. Immunosuppressant treatment leads to various complications that influence extended patient results including nephrotoxicity, infections and malignancies. Abatacept together with mTOR inhibitors demonstrate potential to enhance graft survival and reduce side effects which results in superior long-term results.

Limitations:

The study limitations stem from using a retrospective design that could affect patient choices for selection and the collection of data. Due to the small research participant count and single-site methodology the study results might not apply to broad populations so they require confirmation through expanded and varied population testing.

Future Findings:

Studies should investigate individualized immunosuppression plans which use genetic data and patient-related elements to determine treatment approaches. Medical study must develop additional investigations to evaluate the security and effectiveness of modern immunosuppressive medicines over extended usage periods in addressing infections along with malignancies. The evaluation of emerging therapies for their impact on graft survival requires additional assessment in multiple center studies.

Abbreviations

1. **ESRD** - End-Stage Renal Disease
2. **Canis** - Calcineurin Inhibitors
3. **mTOR** - Mammalian Target of Rapamycin
4. **CNI** - Calcineurin Inhibitor
5. **SPSS** - Statistical Package for the Social Sciences
6. **ANOVA** - Analysis of Variance
7. **SD** - Standard Deviation

Disclaimer: Nil
Conflict of Interest: Nil
Funding Disclosure: Nil

Authors Contribution

Concept & Design of Study: **Najmuddin1,Shahid Rizwan Safir2**
Drafting: **Shahid Iqbal3,ikram ullah4,Haya fazal Maula5,Asad Asghar6**
Data Analysis: **Shahid Iqbal3,ikram ullah4,Haya fazal Maula5,Asad Asghar6**
Critical Review: **Shahid Iqbal3,ikram ullah4,Haya fazal Maula5,Asad Asghar6**
Final Approval of version: **All Mentioned Authors Approved**

Reference

1. Wojciechowski D, Wiseman A. Long-term immunosuppression management: opportunities and uncertainties. Clinical Journal of the American Society of Nephrology. 2021 Aug 1;16(8):1264-71.
2. Pinch NA, Bowman LJ, Taber DJ. Immunosuppression trends in solid organ transplantation: the future of individualization, monitoring, and management. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2021 Jan;41(1):119-31.

3. Szumilas K, Wilk A, Kwasniewski P, Gimped A, Dziedziejko V, Kip M, Pawley A. Current status regarding immunosuppressive treatment in patients after renal transplantation. International journal of molecular sciences. 2023 Jun 18;24(12):10301.
4. Swanskin D, Pogo ED. Introduction to kidney transplantation: long-term management challenges. Clinical Journal of the American Society of Nephrology. 2021 Aug 1;16(8):1262-3.
5. Cheung CY, Tang SC. Personalized immunosuppression after kidney transplantation. Nephrology. 2022 Jun;27(6):475-83.
6. Khan MA, Hanna A, Sridhar S, Chaudhary H, Me HM, Attire RM, Abu Jawed BG. Maintenance Immunosuppression in Kidney Transplantation: A Review of the Current Status and Future Directions. Journal of Clinical Medicine. 2025 Mar 8;14(6):1821.
7. Aiyegbusi O, McGregor E, McManus SK, Stevens KI. Immunosuppression therapy in kidney transplantation. Urologic Clinics. 2022 May 1;49(2):345-60.
8. Agrawal A, Icon MG, Danziger-Isakov L. Long-term infectious complications of kidney transplantation. Clinical Journal of the American Society of Nephrology. 2022 Feb 1;17(2):286-95.
9. Cheungpasitporn W, Lentin KL, Tan JC, Kaufmann M, Calfskin Y, Bunnapradist S, Lam NN, Schnitzler M, Axelrod DA. Immunosuppression considerations for older kidney transplant recipients. Current transplantation reports. 2021 Jun;8:100-10.
10. Pogo ED, Augustine JJ, Arriaga S, Brennan DC, Scold JD. Long-term kidney transplant graft survival—Making progress when most needed. American journal of transplantation. 2021 Aug 1;21(8):2824-32.
11. Gandolfini I, Parmitano A, Fiaccadori E, Craved P, Maggiore U. Detecting, preventing and treating non-adherence to immunosuppression after kidney transplantation. Clinical Kidney Journal. 2022 Jul;15(7):1253-74.
12. Bulbuloglu S, Guns H, Caritas S. The effect of long-term immunosuppressive therapy on gastrointestinal symptoms after kidney transplantation. Transplant Immunology. 2022 Feb 1;70:101515.
13. Lentin KL, Cheungpasitporn W, Xiao H, McAdams-DeMarco M, Lam NN, Sage DL, Bae S, Han JB, Hess GP, Calfskin Y, Randall HB. Immunosuppression regimen use and outcomes in older and younger adult kidney transplant recipients: a national registry analysis. Transplantation. 2021 Aug 1;105(8):1840-9.
14. Etxebarria A, Dies-Martín E, Astigarraga E, Barred-Gómez G. Role of the immune system in renal transplantation, types of response, technical approaches and current challenges. Immune. 2022 Sep 28;2(4):548-70.
15. Barouche S, Bacha MM, Ahmed A, Ben Abdallah T, Abderrahim E. Predicting long-term outcomes of kidney transplantation in the era of artificial intelligence. Scientific Reports. 2023 Dec 2;13(1):21273.
16. Parachinar H, Gulati M. Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs. Immunopharmacology and immunotoxicology. 2021 Nov 2;43(6):651-65.
17. Spires HV, Sharma V, Wowed A, Sivaprakasam R, Augustine T. Robot-assisted kidney transplantation: an update. Clinical kidney journal. 2022 Apr;15(4):635-43.

18. Qi R, Yang C, Zhu T. Advances of contrast-enhanced ultrasonography and electrography in kidney transplantation: from microscopic to microcosmic. Ultrasound in Medicine & Biology. 2021 Feb 1;47(2):177-84.

19. Alas far S, Kodaly L, Schinstock CA. Current therapies in kidney transplant rejection. Journal of Clinical Medicine. 2023 Jul 27;12(15):4927.

20. Klein A, Loopy A, Stegall M, Helanterä I, Kolinski L, Frey E, Aubert O, Diver G, Newell K, Meier-Kristie HU, Menon RB. Qualifying a novel clinical trial endpoint (box) predictive of long-term kidney transplant outcomes. American Journal of Transplantation. 2023 Oct 1;23(10):1496-506.